James Dahlman is a bioengineer / molecular engineer whose work lies at the interface of chemistry, nanotechnology, genomics, and gene editing. His lab focuses on targeted drug delivery, in vivo gene editing, Cas9 therapies, siRNA therapies, and developing new technologies to improve biomaterial design. 

The DahlmanLab is known for applying 'big data' technologies to nanomedicine. The lab is pioneering DNA barcoded nanoparticles; using DNA barcodes, >200 nanoparticles can be analyzed simultaneously in vivo. These nanoparticles are studied directly in vivo, and used to deliver targeted therapies like siRNA, mRNA, or Cas9. As a result of this work, James was named 1 of the 35 most innovative people under the age of 35 by MIT Technnology Review in 2018. James has won many national / international awards, and has published in Science, Nature Nanotechnology, Nature Biotechnology, Nature Cell Biology, Cell, Science Translational Medicine, PNAS, JACS, ACS Nano, Nano Letters, and other journals. James has also designed nanoparticles that efficiently deliver RNAs to the lung and heart. These nanoparticles can deliver 5 siRNAs at once in vivo, and are under consideration for clinical development. As a result, the lab has an interest in immunology and vascular biology. 

James supports entirely new research students come up with independently. To this end, DahlmanLab students learn how to (i) generate new ideas, (ii) select the good ones, and (iii) efficiently test whether the good ideas will actually work. 

Dahlman Lab students learn how to design/characterize/administer nanoparticles, how to isolate different cell types in vivo, how to rationally design DNA to record information, Cas9 therapies, and deep sequencing. As a result, the lab is an interdisciplinary group with students that have backgrounds in medicinal chemistry, BME, bioinformatics, biochemistry, and other fields. The lab welcomes students with all types of scientific backgrounds. The lab firmly stands by students, independent of their personal beliefs, preferences, or backgrounds.

Dr. Gabe Kwong is a Professor in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Tech School of Engineering and Emory School of Medicine. His research program is conducted at the interface of the life sciences, medicine and engineering where a central focus is understanding how to harness the sophisticated defense mechanisms of immune cells to eradicate disease and provide protective immunity. Kwong has pioneered numerous biomedical technologies and published in leading scientific journals such as Nature Biotechnology and Nature Medicine. His work has been profiled broadly including coverage in The Economist, NPR, BBC, and WGBH-2, Boston 's PBS station. Professor Kwong earned his B.S. in Bioengineering with Highest Honors from the University of California, Berkeley and his Ph.D. in Bioengineering from California Institute of Technology with Professor James R. Heath. He conducted postdoctoral studies at Massachusetts Institute of Technology with Professor Sangeeta N. Bhatia. For his work, Dr. Kwong has been awarded the NIH Ruth L. Kirschstein National Research Service Award, named a "Future Leader in Cancer Research and Translational Medicine" by the Massachusetts General Hospital, and awarded the Burroughs Wellcome Fund Career Award at the Scientific Interface, a distinction given to the 10 most innovative bioengineers in the nation. Dr. Kwong holds seven issued or pending patents in cancer nanotechnology.

Felipe trained as a biomedical engineer in his native Colombia before obtaining a PhD from the Biomedical Engineering department of Duke University. At Duke, working in the laboratory of Ashutosh Chilkoti, he focused on the engineering of genetically-encoded, self-assembling protein polymers. An important outcome of this PhD work was the elucidation of sequence rules to program the phase separation behavior of intrinsically disordered proteins (IDPs). Motivated by a newly acquired ability to engineer the phase behavior of IDPs, for his postdoctoral work he turned to their poorly-understood biology. To pursue skin as an outstanding biological system, Felipe joined the group of Elaine Fuchs at Rockefeller University. Felipe’s postdoctoral research led to the discovery that liquid-liquid phase separation drives the process of skin barrier formation. In 2020, he established the Quiroz Lab in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, where he is currently an Assistant Professor. Felipe is the recipient of multiple research awards, including a Career Award at the Scientific Interface from the Burroughs Wellcome Fund and the NIH Director’s New Innovator Award.

Robert E. Guldberg is the DeArmond Executive Director of the Phil and Penny Knight Campus for Accelerating Scientific Impact and Vice President of the University of Oregon. Guldberg’s research is focused on musculoskeletal mechanobiology, regenerative medicine, and orthopaedic medical devices. Over his 25+ year academic career, Dr. Guldberg has produced over 280 peer-reviewed publications, served as an advisor and board member for numerous biotechnology companies, and co-founded six start-ups. He was previously executive director of the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech from 2009-2018. In 2018, he was selected from a national search to lead the Knight Campus as its inaugural permanent Executive Director, where he has led the creation of its strategic plan, hired faculty into the campus’ first building opened in 2020, and launched the University of Oregon’s first ever engineering degree program. In 2021, he led the launch of Phase 2 of the Knight Campus development with the announcement of a second $500 million gift from Phil and Penny Knight. At the national level, Dr. Guldberg is past Chair of the Americas Chapter of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-AM). He currently serves on the Executive Leadership Council of the Wu Tsai Human Performance Alliance, a $220 million global initiative to promote wellness and peak performance through scientific discovery and innovation. Dr. Guldberg is an elected fellow of TERMIS, the American Society of Mechanical Engineers (ASME), the American Institute for Medical and Biological Engineering (AIMBE), the Orthopaedic Research Society (ORS), and the National Academy of Inventors (NAI).

Francesca Storici was born in Trieste, Italy. She graduated in Biology from the University of Trieste. Her Ph.D. in Molecular Genetics was conferred by the International School for Advanced Studies (SISSA), in Trieste in 1998, and she conducted research at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste. From 1999 to 2007 she was an NIH postdoctoral fellow in the Laboratory of Molecular Genetics under the guidance of Dr. Michael A. Resnick at the National Institute of Environmental and Health Sciences (NIEHS, NIH) in the Research Triangle Park of North Carolina, USA. In 2007 she was a Research Assistant Professor at the Gene Therapy Center of the University on North Carolina at Chapel Hill with Dr. R. Jude Samulski. Francesca joined the faculty of the School of Biological Sciences at Georgia Tech in 2007 and received the title of Distinguished Cancer Scientist of the Georgia Research Alliance. She is currently a professor in the School of Biological Sciences at Georgia Tech. Her research is on genome stability, DNA repair and gene targeting.

Dr. Whiteley received his B.S. degree in Zoology in 1995 from the University of Texas at Austin and his Ph.D. in Microbiology from the University of Iowa in 2001. His doctoral research involved quorum sensing and biofilm formation in the bacterium Pseudomonas aeruginosa. Following a Postdoctoral Fellowship at Stanford University in 2002, Dr. Whiteley accepted a position as an assistant professor at the University of Oklahoma/Oklahoma Health Sciences Center. In 2006, Dr. Whiteley moved to the University of Texas at Austin where he was promoted to Professor of Molecular Biosciences and Director of the LaMontagne Center for Infectious Disease. In 2017, he accepted the Bennie H. & Nelson D. Abell Chair and Georgia Research Alliance Eminent Scholar in Molecular and Cellular Biology at Georgia Institute of Technology. He also serves as Associate Director of the CF-Air Center at Emory Medical School. Dr. Whiteley has garnered numerous awards for his work including the Merck Irving S. Sigal Memorial Award for national research excellence, the Burroughs Wellcome Investigators in Pathogenesis of Infectious Disease award, recognition as a Kavli fellow of the National Academy of Sciences, the Dean’s teaching excellence award from UT-Austin, and election to the American Academy of Microbiology.

Ravi Kane is the Garry Betty/V Foundation Chair and GRA Eminent Scholar in Cancer Nanotechnology. He received a B.S. in Chemical Engineering from Stanford University in 1993. Also, he received an M.S. in Chemical Engineering Practice and a Ph.D. in Chemical Engineering from MIT, working with Bob Cohen and Bob Silbey. After postdoctoral research with George Whitesides in the Department of Chemistry and Chemical Biology at Harvard University, he joined Rensselaer Polytechnic Institute (RPI) as an assistant professor in 2001. He was promoted to associate professor in 2006, to full professor in 2007, and to the P.K. Lashmet Professor in 2008. He served as the head of RPI’s Howard P. Isermann Department of Chemical and Biological Engineering before moving to Georgia Tech in 2015. Prof. Kane has graduated 27 Ph.D students and contributed to over 130 scientific publications.

Aditi Das did her BSc. (Hons.) Chemistry from St. Stephen's College Delhi, followed by M.S. (Chemistry) from I.I.T (Kanpur). She received her Ph.D. in Chemistry from Princeton University. She did post-doctoral work with Prof. Steve Sligar. She joined University of Illinois, Urbana-Champaign (UIUC) as a tenure track assistant professor in 2012. In 2019, she was promoted to associate professor with tenure. In 2022, she joined School of Chemistry and Biochemistry at Georgia Institute of Technology as an associate professor with tenure. Her research is in the area of enzymology of oxygenases that are involved lipid metabolism and cannabinoid metabolism.

Das is recipient of an American Heart Associate (AHA) career award and has been funded by National Institute of Health (NIH - NIGMS, NIDA and NCCIH), USDA, and National Multiple Sclerosis Society (NMSS). Her research was recognized by several National awards: Young Investigator award From Eicosanoid Research Foundation, Mary Swartz Rose Young Investigator Award and E.L.R. Stokstad award from American Society for Nutrition (ASN) for outstanding research on bioactive compounds for human health. She is also the recipient of Zoetis Research Excellence Award from her college. She was a co-organizer of the International Conference on Cytochrome P450. Recently her laboratory contributed several papers on cannabinoid metabolism by p450s. In recognition of this work, she was awarded El Sohly award from the ACS-Cannabis division for excellence in Cannabis research and is invited to give plenary lecture at ISSX meeting.  Das is also a standing study section member of BBM NIH study section. 

Throughout my career, my laboratory has studied sphingolipids, a category of lipids that are important in cell structure, signal transduction and cell-cell communication. For more information about what we found, please refer to the Google Scholar or PubMed links below. 

As an Emeritus Professor, I am working on a project that has interested me for a long time--the fact that the active agent in the venom of the brown recluse spider is a sphingomyelinase D that produces a novel product, ceramide 1,3-cyclic phosphate. This activity has also been found in other spiders, bacteria and fungi. With the help of collaborators, I hope to learn more about the organisms that produce and degrade this novel sphingolipid, and possibly find ways to reduce the injury caused by the enzyme when humans encounter it in the environment.